We are pleased to share an upcoming free webinar for the LMNA community focused on an important new area of research: gene therapy for LMNA-related dilated cardiomyopathy (DCM).
The webinar, “LMNA Gene Therapy: A New Approach to LMNA Cardiomyopathy,” will take place on Wednesday, September 9, 2026, from 6:00–7:00 PM ET and is free to attend online.
Organized by the Genetic Cardiomyopathy Awareness Consortium (GCAC), the webinar will feature experts from Nuevocor and Mayo Clinic discussing NVC-001, an investigational gene therapy being studied specifically for LMNA-related DCM.
A new approach to LMNA-related DCM
LMNA-related DCM is a serious inherited form of heart disease that can lead to progressive heart failure, conduction disease and potentially life-threatening arrhythmias. While existing treatments can help manage the consequences of the disease, there are currently no approved therapies specifically targeting its underlying genetic mechanism.
Nuevocor is developing NVC-001 as a one-time investigational gene therapy designed to target the underlying disease mechanism of LMNA-related DCM.
NVC-001 has now entered clinical development through the SUNBEAM-LMNA clinical trial, the first study evaluating the investigational therapy in humans. The study is enrolling participants at clinical sites in the United States and is evaluating the safety and preliminary clinical effects of NVC-001.
For the LMNA community, this represents an important development in the broader effort to move from managing the consequences of LMNA cardiomyopathy toward therapies designed to address mechanisms responsible for the disease itself.
What will the webinar cover?
During the webinar, the speakers will discuss:
- What LMNA-related dilated cardiomyopathy is and how it affects patients and families
- How the investigational NVC-001 gene therapy is designed to work
- The design and goals of the SUNBEAM-LMNA clinical trial
- Who may be eligible to participate in the study
- Important medical and safety considerations for patients considering participation in a gene therapy clinical trial
The session will also provide an opportunity to learn more about the science behind NVC-001 and the rationale for studying this approach in people with LMNA-related DCM.
Speakers
Monica Shah, MD, FACC
Chief Medical Officer, Nuevocor
Dr. Shah is a board-certified heart failure and transplant cardiologist with more than two decades of experience in cardiovascular medicine, clinical research, gene therapy and drug development. As Chief Medical Officer of Nuevocor, she leads the global clinical development of NVC-001.
John Giudicessi, MD, PhD
Cardiologist and Physician-Scientist, Mayo Clinic
Dr. Giudicessi is a cardiologist and physician-scientist whose clinical practice and research focus on inherited cardiovascular diseases, including LMNA cardiomyopathy. His research has contributed to understanding how LMNA genetic variants influence disease progression, arrhythmia risk and clinical outcomes.
Webinar details
Date: Wednesday, September 9, 2026
Time: 6:00–7:00 PM ET
Location: Online
Cost: Free
Unable to attend live? Participants are encouraged to register anyway to receive access to the webinar recording.
At LMNA Cardiac, we closely follow research aimed at developing treatments specifically for LMNA-related cardiac disease. We encourage patients and families interested in emerging therapies and clinical research to join this educational webinar and learn more about the SUNBEAM-LMNA study.
Please note: NVC-001 is an investigational therapy and has not been approved for general clinical use. Information about clinical trials is provided for educational purposes and should not replace discussion with your treating cardiologist or healthcare team.
